



Scalp Psoriasis in Young People: From Descriptive to Analytical Epidemiology and Individualized Homoeopathic Therapeutics: A Community Medicine Review and Proposed Observational Protocol

Dr. Vaibhav Vijaya Ravindra Mahajan^{1*}, Dr. Nayana Sachin Hiray², Dr. Supriya Shekhar Mogre³

¹ BHMS, MD Homoeopathy (HMM), P.G. Hom. (London, UK), F.C.H. Dermatology (MUHS, Nashik), Professor & Head, Department of Community Medicine, Matoshri Homoeopathy College & Hospital, Eklahare, Matoshri Education Campus, Near Odha Gaon, Chhatrapati Sambhajnagar Highway, Eklahare, Nashik, Maharashtra, India

² BHMS, MD Homoeopathy (Homoeopathic Pharmacy), PGDEMS, Associate Professor, Department of Community Medicine, Matoshri Homoeopathy College & Hospital, Eklahare, Matoshri Education Campus, Near Odha Gaon, Chhatrapati Sambhajnagar Highway, Eklahare, Nashik, Maharashtra, India

³ BHMS, MD (Organon of medicine) PGDPC, PGDEMS, Assistant Professor, Department of Community Medicine, Matoshri Homoeopathy College & Hospital, Eklahare, Matoshri Education Campus, Near Odha Gaon, Chhatrapati Sambhajnagar Highway, Eklahare, Nashik, Maharashtra, India

Corresponding Author: *Dr. Vaibhav Vijaya Ravindra Mahajan

DOI: <https://doi.org/10.5281/zenodo.23183050>

Abstract

Background: Psoriasis is a chronic inflammatory skin disorder with substantial clinical, psychological and quality-of-life consequences. The scalp is a frequently involved anatomical site and may create diagnostic and therapeutic challenges because of its visibility, chronicity, recurrence and impact on social and emotional well-being. Contemporary psoriasis guidance recognizes psoriasis as a chronic multisystem inflammatory disease and emphasizes appropriate assessment, topical treatment and attention to associated factors and comorbidities.

Objective: To review scalp psoriasis in younger individuals through the complementary perspectives of descriptive and analytical epidemiology and to propose an observational research framework for evaluating epidemiological characteristics, associated factors, clinical severity and individualized homoeopathic therapeutic management.

Methods: A narrative review framework is proposed encompassing descriptive epidemiological variables including age, sex, residence, occupation, socioeconomic characteristics, seasonality and disease distribution—and analytical variables including family history, psychological stress, smoking, alcohol exposure, infections, trauma, obesity, lifestyle factors, environmental exposures and other potential confounders. The proposed clinical component incorporates standardized assessment of scalp involvement, psoriasis severity, quality of life and treatment response. Homoeopathic treatment is considered as an individualized therapeutic intervention requiring prospective evaluation rather than being assumed to be effective.

Conclusion: A combined descriptive–analytical epidemiological framework may provide a

Manuscript Information

- ISSN No: 3139-9851
- Received: 23-08-2026
- Accepted: 20-09-2026
- Published: 05-10-2026
- IJCATM:1(3); 2026: 46-58
- ©2026, All Rights Reserved
- Plagiarism Checked: Yes
- Peer Review Process: Yes
- Paper type: Research paper

How to Cite

Mahajan VVR, Hiray NS, Mogre SS. Scalp psoriasis in young people: from descriptive to analytical epidemiology and individualized homoeopathic therapeutics: a community medicine review and proposed observational protocol. Int J Curr Acad Trend Multi. 2026;1(3):46-58

[Access this Article Online](#)

more comprehensive understanding of scalp psoriasis among younger individuals. A prospective observational protocol integrating epidemiological characterization, standardized clinical outcomes and individualized homoeopathic prescribing may generate hypotheses and preliminary clinical evidence for future controlled studies.




www.ijcatmjournal.com

KEYWORDS: Scalp Psoriasis; Young Adults; Descriptive Epidemiology; Analytical Epidemiology; Risk Factors; Community Medicine; Homoeopathy; Individualized Treatment; Psoriasis Severity; Quality of Life.

1. INTRODUCTION

Psoriasis is a chronic inflammatory disease with predominantly cutaneous manifestations but broader systemic implications. The scalp represents an important site of disease involvement and may be associated with considerable functional, psychological and social consequences.



The epidemiological study of psoriasis should not be restricted to determining how frequently the disease occurs. Community Medicine requires examination of who develops the disease, where it occurs, when it occurs and what factors may be associated with its occurrence or severity. This creates an important distinction between two complementary epidemiological approaches:

Descriptive Epidemiology

It addresses:

- Person – age, sex, occupation, socioeconomic characteristics
- Place – geographical and environmental distribution
- Time – duration, seasonality, temporal trends
- Disease frequency
- Distribution of clinical manifestations

Analytical Epidemiology

It moves beyond description to investigate possible relationships between:

Exposure → Risk factor → Disease occurrence/severity

For example:

Psychological stress → possible association → psoriasis onset/exacerbation

or

Family history → susceptibility → earlier disease occurrence
However, an observed association does not automatically establish causation. This distinction should remain central to the proposed research methodology.

2. Why Focus on Younger Individuals?

Psoriasis beginning during adolescence or young adulthood can have consequences extending across education, employment, interpersonal relationships and long-term health behaviour.

A young-person-focused study may therefore examine:

- Age at onset
- Duration of disease
- Family history
- Educational status
- Occupation
- Lifestyle
- Psychological stress
- Sleep pattern
- Dietary pattern
- Smoking/tobacco exposure
- Alcohol exposure
- Physical activity
- Obesity/adiposity
- Previous infections
- Scalp trauma or irritation
- Treatment history
- Treatment adherence
- Quality of life.

The research question should preferably define “younger age group” a priori, rather than changing the age boundary after data collection.

For example:

Young adults: 18–40 years

If adolescents are to be included, they should preferably be analysed as a separate subgroup because consent, clinical assessment and ethical considerations differ.

3. Scalp Psoriasis: Clinical and Epidemiological Perspective

Scalp psoriasis may present with:

- Erythematous plaques
- Scaling
- Itching

- Sharply demarcated lesions
- Involvement extending beyond the hairline
- Retroauricular involvement
- Recurrent exacerbations.

Differential diagnosis is important because scalp scaling may also occur in:

- Seborrheic dermatitis
- Tinea capitis
- Atopic dermatitis
- Contact dermatitis
- Lichen simplex chronicus
- Other inflammatory dermatoses.

Therefore, the proposed research should include clear diagnostic criteria and clinical confirmation, rather than relying only on self-reported scalp scaling.

4. Descriptive Epidemiology of Scalp Psoriasis

4.1 Person

The study should describe:

Variable	Examples
Age	18–25, 26–32, 33–40
Sex	Male/Female/Other as appropriate
Education	School/Graduate/Postgraduate
Occupation	Student/Service/Self-employed/Other
Marital status	Appropriate categories
Socioeconomic status	Prespecified classification
Residence	Urban/Semi-urban/Rural
Family history	Present/Absent
Age at onset	Years
Disease duration	Months/years

5. Place

Geographical variables may include:

- Urban versus rural residence
- District
- Occupational environment
- Climatic characteristics
- Environmental exposures
- Water-related factors where scientifically justified
- Occupational stressors
- Access to healthcare.

This can provide a community-oriented epidemiological profile.

6. Time

Temporal variables could include:

- Age at onset
- Duration of disease
- Seasonal exacerbation
- Recurrence pattern
- Treatment response over time
- Number of exacerbations per year.

A longitudinal component would be particularly useful if the study aims to examine treatment outcomes.

7. Analytical Epidemiology

Analytical epidemiology would investigate associations between potential exposures and:

Primary Outcomes

- Presence of scalp psoriasis
- Severity of scalp psoriasis
- Disease duration
- Recurrence/exacerbation.

Secondary Outcomes

- Quality of life
- Psychological burden
- Treatment response
- Functional impairment.

Potential Exposures Include:

Host Factors

- Family history
- Age
- Sex
- Body mass index
- Metabolic characteristics.

Behavioural Factors

- Smoking
- Alcohol
- Physical activity
- Sleep
- Dietary behaviour.

Environmental Factors

- Occupational exposure
- Climate/season
- Pollution where measurable
- Occupational stress.


Psychosocial Factors


- Perceived stress
- Academic stress
- Occupational stress
- Major life events.

The analysis should distinguish confounding, effect modification and genuine associations.

8. Conceptual Epidemiological Model


A Useful Model for the Proposed Study Is:





This Can then Be Linked to:

Clinical assessment → individualized treatment → follow-up → outcome assessment



9. Homoeopathic Therapeutic Perspective

Homoeopathic management should be presented as an individualized clinical intervention, rather than simply assigning one medicine to all patients with scalp psoriasis.

The Therapeutic Assessment May Consider: Disease Characteristics


- Location
- Morphology
- Scaling
- Itching
- Burning
- Aggravating factors
- Ameliorating factors
- Periodicity
- Recurrence.

Individual Characteristics

- Thermal preferences
- Sweating
- Sleep
- Appetite
- Thirst
- Emotional characteristics
- Stress response
- Constitutional features.

Patient-Level Totality

The proposed prescribing model can therefore be represented as:



Importantly, the research protocol should predefine how remedy selection is performed to reduce selective reporting and therapeutic bias.

10. Remedy Differentiation Framework

Instead of presenting a fixed remedy list as evidence of efficacy, the study can examine the frequency and rationale of individualized prescriptions.

Potentially recorded variables:

Domain	Data
Medicine prescribed	Generic remedy name
Potency	Prespecified recording
Repetition	Frequency
Prescription basis	Totality
Dominant symptoms	Recorded
Follow-up	Scheduled
Change in symptoms	Quantified
Adverse events	Recorded
Additional conventional treatment	Documented

This would make the study considerably more reproducible.

11. Proposed Outcome Measures

Primary Outcome

A predefined change in scalp psoriasis severity over the follow-up period.

Possible instruments should be selected according to the exact study design and validated for the population.

Potential measures include:

- Psoriasis Area and Severity Index (PASI)
- Scalp-specific severity assessment
- Physician Global Assessment
- Body Surface Area where appropriate.

Secondary Outcomes

Quality of life

- Dermatology Life Quality Index (DLQI)


Patient-reported outcomes

- Itching
- Scaling
- Burning
- Sleep disturbance
- Embarrassment/social impact.

Epidemiological Outcomes

- Frequency distribution
- Risk-factor associations
- Disease duration
- Recurrence.

A 2023 randomized trial of individualized homeopathic medicines in psoriasis used PASI, PDI and DLQI and reported statistically greater PASI improvement with individualized treatment than placebo after six months, while several other outcomes were not statistically significant. This provides a relevant precedent for incorporating standardized outcomes but does not by itself establish efficacy specifically for young people with scalp psoriasis.



A: “Individualized Homeopathic Therapeutic Management of Scalp Psoriasis: Clinical Indications, Remedy Differentiation.

Homeopathic Therapeutic Management of Scalp Psoriasis

Remedy	Characteristic indications in the proposed homeopathic framework
Graphites	Thick, rough, dry scalp lesions with marked dryness and fissuring; tendency toward sticky/exudative discharge where present; useful differentiation when skin folds and other characteristic Graphites symptoms accompany the scalp condition.
Sulphur	Intense itching, burning and heat; scratching may aggravate irritation; symptoms may be worse from heat or warmth; useful when the characteristic general Sulphur picture accompanies the scalp manifestations.
Arsenicum album	Marked burning with restlessness and anxiety; burning may be associated with dryness; symptoms may show characteristic thermal and temporal modalities.
Petroleum	Extremely dry, rough, cracked skin with a tendency toward fissuring; aggravation may occur in cold weather; consider when the characteristic Petroleum constitutional picture is present.
Psorinum	Severe itching with a tendency toward recurrent/chronic complaints; may be considered when symptoms are markedly worse from warmth/heat and the broader Psorinum picture is present.
Mezereum	Thick crust formation with intense itching/burning; scalp involvement may be prominent; consider particularly when characteristic crusting and neuralgic/burning sensations are present.
Kali arsenicosum	Marked dryness, scaling and burning with a characteristic constitutional picture; may be differentiated from Arsenicum album on the totality rather than scalp symptoms alone.
Sepia	Scalp/skin manifestations accompanied by characteristic hormonal, emotional and constitutional features; especially relevant when the broader Sepia picture is clearly expressed.
Natrum muriaticum	Dry scaling with characteristic constitutional features and emotional modalities; consider when the totality strongly corresponds rather than prescribing solely because of scalp involvement.
Lycopodium	Chronic/recurrent dermatological complaints accompanied by characteristic digestive, constitutional and psychological features; scalp symptoms alone are insufficient for prescription.
Sulphur iodatum	May be considered in chronic inflammatory skin presentations when the totality corresponds; requires differentiation from Sulphur and other remedies.
Kali sulphuricum	Scaling/desquamative skin conditions with characteristic general and local modalities; useful as a differential rather than a diagnosis-based prescription.

Homeopathic management of scalp psoriasis may be approached through individualization rather than diagnosis-based prescribing alone. The diagnosis establishes the clinical disease, while remedy selection is based on the totality of characteristic symptoms, including scalp manifestations, modalities, constitutional characteristics and associated symptoms.

1. Therapeutic Assessment

Before prescribing, the following should be systematically documented:

- Site and distribution of lesions
- Character of scales
- Degree of erythema and infiltration
- Itching, burning or soreness
- Dryness or moisture
- Extension beyond the hairline
- Aggravating and ameliorating factors
- Seasonal variation
- Relationship with stress
- Hair fall or scalp sensitivity
- Associated skin lesions
- Family history
- Previous treatment
- Recurrence pattern
- General constitutional characteristics.

2. Remedy Differentiation with Clear Indications

Important prescribing principle

“Scalp psoriasis” should not automatically lead to a particular remedy.

The prescribing sequence should be:

Clinical diagnosis → individual case-taking → characteristic symptoms → modalities → generals → concomitants → totality → repertorial analysis → materia medica differentiation → individualized prescription.

**3. Practical Remedy-Differentiation Matrix****A. Dry + fissured scalp**

Consider differentiation among:

Petroleum → Graphites → Sulphur

- **Petroleum**: Extreme dryness/cracking, particularly with characteristic cold-weather aggravation.
- **Graphites**: Rough, dry skin with characteristic fissuring/exudative tendencies.
- **Sulphur**: Dryness with prominent itching/burning and characteristic general symptoms.

B. Intense itching + burning

Consider:

Sulphur → Arsenicum album → Psorinum

- **Sulphur**: Itching/burning with heat and characteristic general modalities.
- **Arsenicum album**: Burning + restlessness + anxiety + marked dryness.
- **Psorinum**: Severe itching with recurrent/chronic tendencies and characteristic modalities.

C. Thick crusts

Consider:

Mezereum → Graphites

- **Mezereum**: Prominent thick crusting with intense itching/burning.

- **Graphites**: Characteristic sticky/exudative tendency associated with fissured skin.

D. Chronic Recurrent Scalp Disease

Consider:

Psorinum → Sulphur → constitutional differential

The remedy should be selected only when the complete symptom picture supports the prescription.

4. Acute exacerbation versus chronic management

The protocol should distinguish:

Acute Exacerbation

Document:

- Sudden increase in itching
- Increased erythema
- Increased scaling
- Burning
- Precipitating factors
- Infection or other differential diagnosis.

Chronic Management

Focus on:

- Recurrence pattern
- Constitutional characteristics
- Family history
- Lifestyle factors
- Psychological factors
- Treatment adherence
- Quality of life.

This distinction is particularly important for a Community Medicine study because repeated exacerbation and long-term disease burden may be more informative than a single clinical observation.

5. Homoeopathic Case-Taking Format for the Protocol

A standardized case sheet can contain:

Part A: Dermatological assessment

1. Site
2. Distribution
3. Size
4. Number of lesions
5. Scaling
6. Erythema
7. Infiltration
8. Crusting
9. Itching
10. Burning
11. Pain/soreness.

Part B - Modalities

- Worse from heat
- Worse from cold
- Worse at night
- Worse after bathing

- Worse from sweating
- Worse during stress
- Better from scratching
- Better from cold/warm applications.

Part C - General symptoms

- Thermal preference
- Thirst
- Appetite
- Food desires/aversions
- Sleep
- Sweating
- Bowel habits
- Energy.

Part D - Mental/emotional characteristics

- Stress response
- Anxiety
- Irritability
- Emotional suppression
- Performance/academic stress
- Occupational stress
- Major life events.

Part E - Concomitants

Record symptoms occurring simultaneously with the scalp condition.

6. Proposed Therapeutic Algorithm




Assess:

- Clinical severity
- Scaling
- Itching
- Burning
- Quality of life

- Recurrence
- Adverse events
- Concomitant treatment

Continue / modify / discontinue according to predefined protocol



Safety and Conventional Dermatological Care

The proposed protocol should explicitly state that homoeopathic management should not delay diagnosis or indicated dermatological treatment. Scalp psoriasis can be clinically confused with other scalp disorders, and patients with extensive disease, infection, significant psychological burden, psoriatic arthritis symptoms, or other concerning features should receive appropriate medical/dermatological evaluation. For the research study, all concomitant conventional treatments should be recorded rather than excluded from the dataset without justification. This is essential for controlling confounding and co-intervention bias.

12. Proposed Research Protocol

Proposed study title: Descriptive and Analytical Epidemiology of Scalp Psoriasis in Young Adults and Prospective Evaluation of Individualized Homoeopathic Management: A Community-Based Observational Study

12.1 Study design

A prospective observational study with two integrated components:

- **Phase I: Epidemiological assessment**
Descriptive + analytical epidemiology.
- **Phase II: Prospective clinical follow-up**
Individualized homoeopathic management with standardized outcome assessment.
This design allows epidemiological characteristics and clinical outcomes to be studied within one research framework.

13. Study Population

Target population

Young adults with clinically diagnosed scalp psoriasis.

Suggested age

18–40 years

Study setting

A homoeopathic teaching hospital/dermatology outpatient department/community-based clinical setting.

Suggested duration

12–18 months

14. Inclusion Criteria

Participants may include:

1. Adults aged 18–40 years.
2. Clinically diagnosed scalp psoriasis.
3. Willingness to participate.
4. Written informed consent.
5. Willingness to attend scheduled follow-up.

15. Exclusion Criteria

Potential exclusions:

- Uncertain diagnosis
- Active severe infection requiring urgent treatment
- Major systemic illness affecting assessment
- Inability to complete follow-up
- Concurrent participation in another interventional trial.

Patients requiring urgent conventional dermatological management should receive appropriate care and should not be denied standard treatment because of research participation.

16. Sampling

A consecutive sampling strategy could be used in the clinical setting.

Sample size should be calculated before recruitment, based on the primary epidemiological or clinical outcome.

For analytical epidemiology, sample size may depend upon:

- Expected prevalence/exposure frequency
- Expected effect size
- Alpha
- Statistical power
- Number of covariates
- Anticipated loss to follow-up.

17. Data Collection Tool

A structured Case Record Form can contain:

- **Section A:** Sociodemographic profile
- **Section B:** Epidemiological profile
- **Section C:** Clinical characteristics
- **Section D:** Risk-factor assessment
- **Section E:** Psychological/lifestyle variables
- **Section F:** Homoeopathic case-taking
- **Section G:** Remedy prescription
- **Section H:** Follow-up
- **Section I:** Outcome assessment.

18. Statistical Analysis

Descriptive analysis

- Mean $\pm$ SD
- Median and IQR
- Frequencies
- Percentages.

Analytical analysis

Depending on the data:

- Chi-square/Fisher's exact test
- T-test/Mann–Whitney U
- ANOVA/Kruskal–Wallis
- Correlation analysis
- Logistic regression
- Linear regression
- Multivariable regression.

For example:

- **Dependent variable:** clinically significant scalp psoriasis severity
- **Independent variables:** age, sex, family history, BMI, smoking, stress, sleep, occupation, disease duration and other pre-specified variables.
- Adjusted estimates with 95% confidence intervals should be reported rather than relying only on p-values.

19. Confounding and Bias

Important potential confounders include:

- Age
- Sex
- Bmi
- Family history
- Disease duration
- Smoking
- Alcohol
- Socioeconomic status
- Previous treatment.

Potential biases include:

- **Selection bias**
Patients attending a homoeopathic hospital may not represent all young people with scalp psoriasis.
- **Recall bias**
Participants may inaccurately recall previous triggers or treatments.

- **Observer bias**
Clinical assessment may vary between investigators.
- **Treatment-selection bias**
The choice of individualized remedy is not randomized.
Therefore, blinding and independent outcome assessment should be considered where feasible.


20. Proposed Epidemiological Comparison

The article can present the methodological distinction in a simple table:

Descriptive Epidemiology	Analytical Epidemiology
Who?	Why/with what factors?
Where?	Which exposures are associated?
When?	What is the strength of association?
Distribution	Exposure–outcome relationship
Person–Place–Time	Risk factors/confounders
Frequency	Association
Hypothesis generation	Hypothesis testing

This is an excellent **Community Medicine teaching and research component** of the article.

21. Proposed Study Flow



22. Ethical Considerations

The protocol should include:

- Institutional Ethics Committee approval
- Written informed consent
- Confidentiality
- Coded participant identification
- Right to withdraw
- Documentation of concomitant treatment
- Adverse-event monitoring

- Referral when conventional dermatological care is clinically indicated.

The study should not imply that individualized homoeopathy replaces evidence-based dermatological treatment.

23. Strengths of the Proposed Protocol


The proposed model has several methodological advantages:

1. Integrates descriptive and analytical epidemiology.
2. Focuses on a clearly defined younger population.
3. Separates epidemiological association from therapeutic outcome.
4. Uses standardized clinical outcomes.
5. Incorporates quality-of-life assessment.
6. Records individualized homoeopathic prescribing transparently.
7. Allows assessment of potential confounders.
8. Can generate hypotheses for a subsequent controlled trial.
9. Can be reported according to STROBE principles for observational research. STROBE specifically recommends clear reporting of study design, setting, participants, variables, measurement, bias, study size and statistical methods.

24. Important Limitation

A prospective observational study of individualized homoeopathic treatment cannot by itself establish that homoeopathy caused improvement, because treatment is not randomly assigned and there may be regression to the mean, natural disease fluctuation, concomitant treatment, placebo/contextual effects and other confounding factors.

Therefore, the logical research pathway would be:



This would give the project a stronger evidence-development pathway.

25. Future Research Model

A particularly innovative direction would be to develop a “Scalp Psoriasis Epidemiological–Individualization Framework (SPEIF)”:

- **Domain 1:** Epidemiological profile
Person + Place + Time
- **Domain 2:** Analytical profile
Risk factors + exposures + confounders
- **Domain 3:** Clinical profile
Distribution + severity + symptoms
- **Domain 4:** Individualization

Patient-specific symptom pattern

• **Domain 5:** Outcome

Disease severity + quality of life + recurrence

This could become the conceptual model for a subsequent prospective study.

Epidemiology and Individualized Management of Scalp Psoriasis

Authors Contributions

Author 1: Prof. Dr. Vaibhav Vijaya Ravindra Mahajan

- Conceptualization of the article and research question.
- Development of the descriptive and analytical epidemiological framework.
- Development of the proposed observational research protocol.
- Literature review and synthesis of epidemiological evidence.
- Development of the Community Medicine perspective.
- Development of the individualized homoeopathic therapeutic framework.
- Development of methodological and statistical considerations.
- Preparation and critical revision of the manuscript.
- Final approval of the version to be submitted.

Author 2: Dr Nayana Sachin Hiray,

Author 3: Dr. Supriya Shekhar Mogre

- Literature search and evidence identification.
- Review of dermatological and clinical aspects of scalp psoriasis.
- Contribution to clinical assessment and differential diagnostic framework.
- Contribution to homoeopathic case-taking and therapeutic individualization sections.
- Review of outcome measures including disease severity and quality-of-life assessment.
- Critical review and editing of the manuscript.
- Final approval of the version to be submitted.

3. Ethics Statement

As this manuscript is a review and proposed research protocol, no primary participant-level data are reported in the present article.

If the proposed observational study is subsequently undertaken, it should receive approval from the appropriate Institutional Ethics Committee/Institutional Review Board before participant recruitment. Written informed consent should be obtained from all participants.

Participants should be informed about the study objectives, procedures, potential risks and benefits, confidentiality, voluntary participation and their right to withdraw without affecting their clinical care.

4. Consent for Publication

No identifiable individual participant information or photographs are presented in this review/protocol manuscript.

If identifiable clinical photographs or case information are included in a subsequent study publication, appropriate written consent for publication should be obtained.

5. Funding Statement: No specific external funding was received for the preparation of this review and proposed research protocol.

6. Conflict of Interest

The authors declare that they have no financial or non-financial conflicts of interest directly related to this manuscript.

7. Data Availability Statement

No original participant-level dataset was generated or analyzed for this review article. Data generated during a future implementation of the proposed protocol should be managed according to Institutional Ethics Committee requirements and applicable data-protection standards.

8. Acknowledgements

The authors acknowledge the contribution of the scientific literature, epidemiological research databases, dermatology guidelines and methodological reporting frameworks that informed the development of this review and proposed protocol.

9. Reporting Guideline

The proposed observational study should be designed and reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations. STROBE provides guidance for reporting observational studies, including cohort, case-control and cross-sectional designs.

For the eventual research manuscript, the investigators should report:

- Study design
- Study setting
- Participant selection
- Eligibility criteria
- Variables
- Measurement methods
- Potential sources of bias
- Sample-size determination
- Statistical methods
- Missing-data management
- Participant flow
- Descriptive findings
- Analytical findings
- Limitations
- Interpretation.

10. Clinical Outcome Framework

For the future prospective study, disease severity should preferably be measured using standardized instruments rather than subjective descriptions alone.

Potential outcomes include:

Primary outcome

Change in objectively measured psoriasis severity.


Secondary outcomes

- Psoriasis Area and Severity Index (PASI)
- Scalp-specific clinical severity
- Physician Global Assessment
- Pruritus intensity
- Scaling
- Erythema
- Quality of life
- Treatment adherence
- Recurrence/exacerbation
- Patient-reported improvement.

PASI was originally developed as a standardized method for assessing psoriasis severity, while the Dermatology Life Quality Index (DLQI) provides a validated approach for assessing the effect of dermatological disease on quality of life. Current dermatology guidance also recognizes PASI, body-surface-area measures, global assessment and quality-of-life instruments as tools that can be used in appropriate clinical or research settings.

14. Proposed Conceptual Framework

Descriptive epidemiology



Characteristic symptoms

↓

Individual totality

↓

Remedy differentiation

↓

Individualized prescription

↓

Outcome Assessment

Clinical severity + Symptoms + Quality of Life + Recurrence

Differential Diagnosis

The proposed protocol should explicitly distinguish scalp psoriasis from clinically similar disorders, including:

- Seborrhoeic dermatitis
- Tinea capitis
- Atopic dermatitis
- Allergic/irritant contact dermatitis
- Lichen simplex chronicus
- Pityriasis amiantacea associated with different underlying dermatoses
- Other inflammatory or infectious scalp disorders.

Scalp psoriasis is characterized clinically by well-demarcated erythematous plaques and scaling, and diagnosis may require differentiation from other scalp disorders.

Public Health Implications

A community-oriented approach to scalp psoriasis should extend beyond treatment of visible lesions.


Potential public-health interventions include:

- Awareness regarding chronicity and recurrence
- Reduction of stigma
- Early clinical assessment
- Identification of modifiable risk factors
- Lifestyle counselling
- Appropriate referral
- Screening for clinically relevant comorbidities
- Psychological support where required
- Patient education regarding adherence
- Avoidance of potentially harmful self-medication.

Psoriasis has important psychosocial and systemic implications, making multidisciplinary assessment relevant to public-health planning.

20. Future Research Direction

The proposed research programme can progress through four stages:



↓
Stage IV

Randomized controlled trial with appropriate comparator and
blinded outcome assessment where feasible

This staged model would allow epidemiological observations to generate hypotheses that can subsequently be tested with increasingly rigorous designs.

A randomized placebo-controlled study of individualized homeopathic medicines in psoriasis has already been reported, using PASI, PDI and DLQI as outcomes; the investigators themselves concluded that further research was warranted. This supports the value of developing more targeted and methodologically rigorous studies, while not establishing efficacy specifically for young adults with scalp psoriasis.

21. CONCLUSION

Scalp psoriasis in younger individuals provides a useful model for integrating descriptive and analytical epidemiology with patient-centred clinical research. Descriptive epidemiology establishes the distribution of disease according to person, place and time, whereas analytical epidemiology investigates potential associations between exposures and disease characteristics. A prospective protocol incorporating standardized severity assessment, quality-of-life measurement, transparent individualized prescribing, appropriate control of confounding and STROBE-oriented reporting can provide a scientifically structured foundation for future research. The proposed framework should be considered hypothesis-generating until supported by appropriately designed comparative clinical studies.

REFERENCES

1. Augustin M, Langenbruch A, Radtke MA. Global state of psoriasis disease epidemiology: A workshop report. *British Journal of Dermatology*. 2017;177(1):e7. <https://doi.org/10.1111/bjd.15610>
2. Boehncke WH, Schön MP. Psoriasis. *The Lancet*. 2015;386(9997):983–994. [https://doi.org/10.1016/S0140-6736\(14\)61909-7](https://doi.org/10.1016/S0140-6736(14)61909-7)
3. Boehncke WH, Brembilla NC. Unmet needs in the field of psoriasis: Pathogenesis, clinical challenges and perspectives. *Clinical Reviews in Allergy & Immunology*. 2018;55:1–9.
4. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. *Indian Journal of Dermatology, Venereology and Leprology*. 2010;76(6):595–601. <https://doi.org/10.4103/0378-6323.72437>
5. Elmetts CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, *et al.* Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *Journal of the American Academy of Dermatology*. 2021;84(5):1305–1317.
6. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—A simple practical measure for routine clinical use. *Clinical and Experimental Dermatology*. 1994;19(3):210–216. <https://doi.org/10.1111/j.1365-2230.1994.tb01167.x>
7. Fredriksson T, Pettersson U. Severe psoriasis—Oral therapy with a new retinoid. *Dermatologica*. 1978;157(4):238–244. <https://doi.org/10.1159/000250839>
8. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. *The Lancet*. 2021;397(10281):1301–1315. [https://doi.org/10.1016/S0140-6736\(20\)32549-6](https://doi.org/10.1016/S0140-6736(20)32549-6)
9. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA*. 2004;291(20):2519–2525. <https://doi.org/10.1001/jama.291.20.2519>
10. Kim GK, Del Rosso JQ. Drug-provoked psoriasis: Is it drug induced or drug aggravated? *Journal of Clinical and Aesthetic Dermatology*. 2010;3(1):32–38.
11. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. *Journal of the European Academy of Dermatology and Venereology*. 2017;31(2):205–212. <https://doi.org/10.1111/jdv.13854>
12. Menter A, Strober BE, Kaplan DH, Langley RG, Lebwohl M, Ohtsuki M, *et al.* Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy. *Journal of the American Academy of Dermatology*. 2019;81(3):775–804.
13. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. *Journal of Investigative Dermatology*. 2013;133(2):377–385. <https://doi.org/10.1038/jid.2012.339>
14. Papp K, Berth-Jones J, Kragballe K, Wozel G, de la Brassinne M. Scalp psoriasis: A review of current topical treatment options. *Journal of the European Academy of Dermatology and Venereology*. 2007;21(9):1151–1160. <https://doi.org/10.1111/j.1468-3083.2007.02424.x>
15. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. *International Journal of Molecular Sciences*. 2019;20(6):1475. <https://doi.org/10.3390/ijms20061475>
16. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, *et al.* Psoriasis and comorbid diseases: Epidemiology. *Journal of the American Academy of Dermatology*. 2017;76(3):377–390. <https://doi.org/10.1016/j.jaad.2016.07.064>

17. van de Kerkhof PCM, Franssen ME. Psoriasis of the scalp: Diagnosis and management. *American Journal of Clinical Dermatology*. 2001;2(3):159–165.
18. <https://doi.org/10.2165/00128071-200102030-00005>
19. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, *et al.* Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. *PLoS Medicine*. 2007;4(10). <https://doi.org/10.1371/journal.pmed.0040297>
20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, for the STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. *PLoS Medicine*. 2007;4(10). <https://doi.org/10.1371/journal.pmed.0040296>
21. Wang K, Zhao Y, Cao X. Global burden and future trends in psoriasis epidemiology: Insights from the Global Burden of Disease Study 2019 and predictions to 2030. *Archives of Dermatological Research*. 2024;316:114. <https://doi.org/10.1007/s00403-024-02846-z>
22. World Health Organization. Global report on psoriasis. World Health Organization; 2016.
23. Armstrong AW, Read C, *et al.* Pathophysiology, clinical presentation, and treatment of psoriasis: A review. *JAMA*. 2020;323(19):1945–1960.
24. Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Hughes C, *et al.* Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. *Cochrane Database of Systematic Reviews*. 2021;2021(4). <https://doi.org/10.1002/14651858.CD011535.pub4>
25. World Health Organization. WHO guideline on the management of psoriasis. World Health Organization; 2023.
26. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: A comparative overview. *Evidence-Based Complementary and Alternative Medicine*. 2005;2(4):465–473. <https://doi.org/10.1093/ecam/neh140>

Creative Commons (CC) License

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution–Non-Commercial–No Derivatives 4.0 International (CC BY-NC-ND 4.0) license. This license permits sharing and redistribution of the article in any medium or format for non-commercial purposes only, provided that appropriate credit is given to the original author(s) and source. No modifications, adaptations, or derivative works are permitted under this license.

About the Author



Prof. Dr. Vaibhav Vijaya Ravindra Mahajan is a distinguished homoeopathic physician and academician. He holds an M.D. in Homoeopathy (HMM), P.G. Homoeopathy from London, UK, and F.C.H. in Dermatology from MUHS, Nashik. He is a Professor and Head of the Department of Community Medicine, with expertise in homoeopathy, dermatology, and community healthcare.



Dr. Nayana Sachin Hiray holds a BHMS, MD in Homoeopathy (Homoeopathic Pharmacy), and PGDEMS. She is an Associate Professor in the Department of Community Medicine at Matoshri Homoeopathy College & Hospital, Eklahare, Nashik, Maharashtra, India. Her academic interests include Community Medicine, Homoeopathic Pharmacy, and healthcare education.



Dr. Supriya Shekhar Mogre holds a BHMS, MD in Organon of Medicine, PGDPC, and PGDEMS. She is an Assistant Professor in the Department of Community Medicine at Matoshri Homoeopathy College & Hospital, Eklahare, Nashik, Maharashtra, India. Her academic interests include Community Medicine, Homoeopathic education, and healthcare practices.